These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2070208)

  • 1. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostatic cancer.
    Goodman CM; Cumming JA; Ritchie AW; Chisholm GD
    Br J Urol; 1991 Jun; 67(6):622-5. PubMed ID: 2070208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
    Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.
    Merrick MV; Ding CL; Chisholm GD; Elton RA
    Br J Urol; 1985 Dec; 57(6):715-20. PubMed ID: 4084732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase (PAP) in blood by PAP RIA kit "EIKEN" (author's transl)].
    Kida T; Higuchi Y
    Kaku Igaku; 1981 Aug; 18(7):907-15. PubMed ID: 7321322
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies on prognosis of prostate cancer with bone metastasis by using pretreatment bone scintigraphy].
    Kubota Y; Numasawa K; Suzuki H; Kakizaki H; Suzuki K
    Hinyokika Kiyo; 1989 Oct; 35(10):1693-9. PubMed ID: 2610178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of prostate specific antigen that predict skeletal spread in prostate cancer.
    Pantelides ML; Bowman SP; George NJ
    Br J Urol; 1992 Sep; 70(3):299-303. PubMed ID: 1384921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical study on prognosis of metastatic prostate cancer based on extent of disease on pretreatment bone scintigraphy.
    Fuse H; Mizuno I; Yokoyama T; Sakamoto M; Katayama T
    Int Urol Nephrol; 1995; 27(5):567-74. PubMed ID: 8775041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reappraisal of serial isotope bone scans in prostate cancer.
    O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
    Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of bone scanning in the assessment of prostatic carcinoma.
    McGregor B; Tulloch AG; Quinlan MF; Lovegrove F
    Br J Urol; 1978 May; 50(3):178-81. PubMed ID: 753456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic association of PAP and PSA determinations to bone scintigraphy in prostatic cancer.
    Fincker F; Sauvan R; Pasquier J
    Am J Clin Oncol; 1988; 11 Suppl 2():S68-70. PubMed ID: 2468277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The usefulness of early whole body bone scintigraphy in the detection of bone metastasis from prostatic cancer].
    Otsuka N; Fukunaga M; Furukawa Y; Tanaka H
    Kaku Igaku; 1994 Jun; 31(6):541-50. PubMed ID: 7520953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity.
    Reikerås O; Due J; Sundsfjord JA
    Int Urol Nephrol; 1988; 20(1):51-4. PubMed ID: 3283071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relation between serum PAP (prostate acid phosphatase) and bone scintigraphy in prostatic cancer].
    Aizawa T; Itoh T; Tsujino S; Namiki K; Miki M
    Kaku Igaku; 1992 Nov; 29(11):1277-83. PubMed ID: 1484418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow aspiration biopsy and bone scanning in the staging of prostatic cancer.
    Varenhorst E; Alund G; Lindström E; Månson JC
    Br J Urol; 1983 Oct; 55(5):534-7. PubMed ID: 6626900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2).
    Jørgensen T; Müller C; Kaalhus O; Danielsen HE; Tveter KJ
    Eur Urol; 1995; 28(1):40-6. PubMed ID: 8521893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial bone scanning in the evaluation of stage and clinical course in carcinoma of the prostate.
    Johansson JE; Beckman KW; Lindell D; Lingårdh ; Rydman H; Vikterlöf KJ
    Scand J Urol Nephrol Suppl; 1980; 55():31-6. PubMed ID: 6938033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.